Remove contact
article thumbnail

FDA Publishes New Guidance on Cybersecurity in Medical Devices

McGuire Wood

Food and Drug Administration (FDA) released updated guidance regarding cybersecurity safety requirements for medical devices. To strengthen the QSR metrics, the FDA recommends implementing a secure product development framework (SPDF) to address cybersecurity risks. 27, 2023, the U.S.

FDA 52
article thumbnail

FDA Issues Draft Guidance on Labeling of Plant-Based Milk Alternatives

Health Law Advisor

Food and Drug Administration (“FDA”) announced a much-anticipated draft guidance regarding the naming and labeling of plant-based milk alternatives. [1] The dairy industry has lobbied both federal and state governments to restrict the use of “milk” to only fluid “obtained by the complete milking of one or more healthy cows.” [2]

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Are Essential Oils FDA-Approved?

Florida Health Care Law Firm

The FDA does not regulate essential oils, just like it doesn’t regulate herbs or supplements. That means that there is no FDA approval for any essential oil. But if they say that their product is FDA-approved to do something specific, that is incorrect and they are open to fines and could be shut down.

FDA 52
article thumbnail

Unpacking Averages: Exploring New Data on FDA Responses to FOIA Requests

Health Law Advisor

To provide more value to readers, I’ve started submitting FOIA requests for unpublished data to produce additional insights into how FDA works. And what better first topic than data on FDA responses to FOIA requests. FDA has been releasing data on its FOIA process, specifically its FOIA logs , for a few years. We were wrong.

FDA 52
article thumbnail

FDA Expands Access to Mifepristone: Next Steps for Providers and Retail Pharmacies

Hall Render

Food and Drug Administration (“FDA”) released an updated Mifepristone Risk Evaluation and Mitigation Strategy (the “Mifepristone REMS Program”), which reverses the requirement that the drug be dispensed directly to a patient by certified prescriber in a clinic or a medical office (the “in-person dispensing requirement”).

FDA 40
article thumbnail

Incorporation by Reference Does Not Create a Material Condition of Payment

Hall Render

Defendant pharmaceutical manufacturers applied for and received approval from the FDA to manufacture Gamunex at a facility converted for that purpose. FDA regulations require current Good Manufacturing Practices [cGMP] to be met or the drug shall be deemed adulterated and prohibited from sale. Your primary Hall Render contact.

FDA 40
article thumbnail

U.S. Food and Drug Administration Issues Draft Guidance Updating Good Clinical Practices 

Hall Render

Food and Drug Administration (“FDA”) released draft guidance (“Draft Guidance”) updating Good Clinical Practices (“GCPs”) recommendations for interventional clinical trials involving human subjects. Data Governance The Draft Guidance also strengthens the existing focus on data governance from both a sponsor and investigator perspective.

FDA 40